NasdaqGS:TXG

Stock Analysis Report

Executive Summary

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems.

Rewards

Revenue is forecast to grow 34.64% per year

Revenue grew by 73.7% over the past year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months



Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has 10x Genomics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TXG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.1%

TXG

0.4%

US Life Sciences

0.06%

US Market


1 Year Return

n/a

TXG

18.6%

US Life Sciences

19.4%

US Market

Return vs Industry: Insufficient data to determine how TXG performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how TXG performed against the US Market.


Shareholder returns

TXGIndustryMarket
7 Day4.1%0.4%0.06%
30 Day7.9%-1.9%1.1%
90 Day46.0%8.7%8.9%
1 Yearn/a18.9%18.6%21.9%19.4%
3 Yearn/a93.9%92.6%48.9%39.3%
5 Yearn/a122.1%119.0%71.9%53.1%

Price Volatility Vs. Market

How volatile is 10x Genomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is 10x Genomics undervalued compared to its fair value and its price relative to the market?

20.58x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TXG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TXG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TXG is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: TXG is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TXG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TXG is overvalued based on its PB Ratio (21.1x) compared to the US Life Sciences industry average (5.8x).


Next Steps

Future Growth

How is 10x Genomics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

57.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TXG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TXG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TXG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TXG's revenue (34.6% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: TXG's revenue (34.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TXG is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has 10x Genomics performed over the past 5 years?

-12.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: TXG is currently unprofitable.

Growing Profit Margin: TXG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TXG's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare TXG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TXG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.6%).


Return on Equity

High ROE: TXG has a negative Return on Equity (-23.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is 10x Genomics's financial position?


Financial Position Analysis

Short Term Liabilities: TXG's short term assets ($474.1M) exceed its short term liabilities ($48.2M).

Long Term Liabilities: TXG's short term assets ($474.1M) exceed its long term liabilities ($103.1M).


Debt to Equity History and Analysis

Debt Level: TXG's debt to equity ratio (7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TXG's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: TXG has a low level of unsold assets or inventory.

Debt Coverage by Assets: TXG's debt is covered by short term assets (assets are 16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TXG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TXG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -49.7% each year


Next Steps

Dividend

What is 10x Genomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage0.3%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate TXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TXG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TXG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TXG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TXG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Serge Saxonov (42yo)

7.6yrs

Tenure

US$1,084,275

Compensation

Dr. Serge Saxonov Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at QuantaLife, w ...


CEO Compensation Analysis

Compensation vs Market: Serge's total compensation ($USD1.08M) is below average for companies of similar size in the US market ($USD6.26M).

Compensation vs Earnings: Insufficient data to compare Serge's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Serge Saxonov
Co-Founder7.6yrsUS$1.08m3.35% $290.5m
Justin McAnear
Chief Financial Officer1.3yrsUS$1.74mno data
Eric Whitaker
General Counsel2.6yrsUS$874.78k0.087% $7.6m
Benjamin Hindson
Co-Founder7.6yrsno data3.19% $276.8m
Paul Wyatt
Vice President of Operations0yrsno datano data
Jonathan Schimmel
Vice President of Global Support & Sales Operations3.4yrsno datano data
Sam Ropp
Senior Vice President of Global Sales1.1yrsno datano data
Jean Philibert
Chief People Officer1.8yrsno datano data
Michael Schnall-Levin
Senior Vice President of R&D & Founding Scientist1.1yrsno datano data
Alexander Wong
Senior Vice President of Product1.1yrsno datano data

1.8yrs

Average Tenure

44yo

Average Age

Experienced Management: TXG's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Serge Saxonov
Co-Founder7.6yrsUS$1.08m3.35% $290.5m
Benjamin Hindson
Co-Founder7.6yrsno data3.19% $276.8m
Bryan Roberts
Independent Director6.3yrsno datano data
John Stuelpnagel
Chairman6.5yrsUS$240.44k2.65% $229.6m
Shehnaaz Suliman
Independent Director0.5yrsno datano data
Mathai Mammen
Independent Director2.5yrsno datano data
Sridhar Kosaraju
Independent Director0.8yrsno data0.011% $977.0k

6.3yrs

Average Tenure

47yo

Average Age

Experienced Board: TXG's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: TXG only recently listed within the past 12 months, with total shares outstanding growing by 42.4% in the past year..


Top Shareholders

Company Information

10x Genomics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: 10x Genomics, Inc.
  • Ticker: TXG
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$8.676b
  • Shares outstanding: 96.17m
  • Website: https://www.10xgenomics.com

Number of Employees


Location

  • 10x Genomics, Inc.
  • 6230 Stoneridge Mall Road
  • Pleasanton
  • California
  • 94588
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TXGNasdaqGS (Nasdaq Global Select)YesClass A Common StockUSUSDSep 2019
1KJBST (Boerse-Stuttgart)YesClass A Common StockDEEURSep 2019
1KJDB (Deutsche Boerse AG)YesClass A Common StockDEEURSep 2019

Biography

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems. The company serves researchers in approximately 40 countries. Its customers include a range of academic, government, biopharmaceutical, biotechnology, and other institutions worldwide. 10X Genomics, Inc. was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. The company was incorporated in 2012 and is based in Pleasanton, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 02:36
End of Day Share Price2020/02/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.